At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
In Brief
A clinical study evaluating aPTT guided heparin management and Anti-factor Xa guided heparin management for Left Sided Heart Failure and 7 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study evaluates two different methods for monitoring a patient's anti-clotting \[heparin\] therapy after they receive a heart pump implant \[left ventricular assist device -LVAD\]. One method tests for how long it takes the patient's blood to clot and uses that to determine if they are on the right dose of heparin. The other method uses a more direct measure of how much heparin is in the blood. The hypothesis is that the method that more directly measures how much heparin is in the patient's blood will provide better medical results for the patient's care after they have the heart pump implant. To that end, the investigators are conducting this feasibility trial to establish the logistics associated with the implementation of these heparin monitoring approaches.
Study Details
Timeline
Interventions
post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device